Australia
· Delayed Price · Currency is AUD Cynata Therapeutics Statistics
Total Valuation
ASX:CYP has a market cap or net worth of AUD 42.93 million. The enterprise value is 32.42 million.
| Market Cap | 42.93M |
| Enterprise Value | 32.42M |
Important Dates
The next estimated earnings date is Wednesday, May 28, 2025.
| Earnings Date | May 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ASX:CYP has 225.95 million shares outstanding. The number of shares has increased by 11.56% in one year.
| Current Share Class | 225.95M |
| Shares Outstanding | 225.95M |
| Shares Change (YoY) | +11.56% |
| Shares Change (QoQ) | +2.54% |
| Owned by Insiders (%) | 8.26% |
| Owned by Institutions (%) | 4.21% |
| Float | 175.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.67 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.66 |
| EV / Sales | 18.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.01 |
Financial Position
The company has a current ratio of 7.91
| Current Ratio | 7.91 |
| Quick Ratio | 7.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.53% and return on invested capital (ROIC) is -49.14%.
| Return on Equity (ROE) | -74.53% |
| Return on Assets (ROA) | -44.37% |
| Return on Invested Capital (ROIC) | -49.14% |
| Return on Capital Employed (ROCE) | -81.30% |
| Revenue Per Employee | 870,028 |
| Profits Per Employee | -4.43M |
| Employee Count | 2 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.91% in the last 52 weeks. The beta is 0.82, so ASX:CYP's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -30.91% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 47.33 |
| Average Volume (20 Days) | 134,651 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:CYP had revenue of AUD 1.74 million and -8.85 million in losses. Loss per share was -0.05.
| Revenue | 1.74M |
| Gross Profit | 1.74M |
| Operating Income | -9.34M |
| Pretax Income | -8.85M |
| Net Income | -8.85M |
| EBITDA | -9.06M |
| EBIT | -9.34M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 10.51 million in cash and n/a in debt, giving a net cash position of 10.51 million or 0.05 per share.
| Cash & Cash Equivalents | 10.51M |
| Total Debt | n/a |
| Net Cash | 10.51M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 11.49M |
| Book Value Per Share | 0.05 |
| Working Capital | 9.49M |
Cash Flow
In the last 12 months, operating cash flow was -8.03 million and capital expenditures -50,000, giving a free cash flow of -8.08 million.
| Operating Cash Flow | -8.03M |
| Capital Expenditures | -50,000 |
| Free Cash Flow | -8.08M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -536.70% |
| Pretax Margin | -508.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ASX:CYP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.56% |
| Shareholder Yield | n/a |
| Earnings Yield | -20.62% |
| FCF Yield | -18.83% |
Stock Splits
The last stock split was on October 31, 2013. It was a reverse split with a ratio of 0.05.
| Last Split Date | Oct 31, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
ASX:CYP has an Altman Z-Score of 6.47.
| Altman Z-Score | 6.47 |
| Piotroski F-Score | n/a |